Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial.

Mov Disord Clin Pract · 2025 · PMC12187963 · PMID 40008823

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

Subjective functional impact of LID (MDS‐UPDRS 4.2) showed a numerical trend towards dose‐dependent improvements vs. placebo.

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.